Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Bryan Arnold who wrote (4336)	5/19/1998 3:32:00 PM
From: Steve Fancy	Respond to of 6136

I was reassured by the projections of no real threats to Viracept in their opinion over the next 2-3 years. Although their price target is $40 over 12-18 months, Merrill in my experience has a habit of extremely conservative price targets. Any solid sign that AGPH may have a winner product in their pipeline could and should IMO, add some speculative premium back into the stock. Many of the regular posters here seem to have unbending confidence in the pipeline. If they are right, I would hope we'd see some of this speculative premium before the year is out. If not, at least there does not appear to be much built in to lose if less then optimal results of other drug trials. sf

To: Bryan Arnold who wrote (4336)	5/19/1998 3:57:00 PM
From: Robert L. Ray	Read Replies (2) \| Respond to of 6136

>I still don't understand how they are going to only be able to grow >their earnings by 100% from now until the year 2002. I would think >that it would be much higher then that. It would appear the reason is the marketing deals with Japan Tobacco and Roach for the Japanese and European sales. Sheese the Roche deal sounds awful from an AGPH standpoint. It basicaly amounts to a 10% royalty on sales is what the article said. Does this sound ridiculously low to anyone else? Looks like they could have cut a better deal than that.